RedHill Biopharma Statistics
Share Statistics
RedHill Biopharma has 4.42K
shares outstanding. The number of shares has increased by -96%
in one year.
| Shares Outstanding | 4.42K |
| Shares Change (YoY) | -96% |
| Shares Change (QoQ) | -0.03% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 21,163 |
| FTD / Avg. Volume | 7.19% |
Short Selling Information
The latest short interest is 54.66K, so 3.09% of the outstanding
shares have been sold short.
| Short Interest | 54.66K |
| Short % of Shares Out | 3.09% |
| Short % of Float | 3.61% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.01 and the forward
PE ratio is null.
RedHill Biopharma's PEG ratio is
0.
| PE Ratio | -0.01 |
| Forward PE | n/a |
| PS Ratio | 0.01 |
| Forward PS | 0 |
| PB Ratio | -0.02 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for RedHill Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.54,
with a Debt / Equity ratio of -0.08.
| Current Ratio | 0.54 |
| Quick Ratio | 0.37 |
| Debt / Equity | -0.08 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.04 |
| Interest Coverage | -265.69 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $229,800 |
| Profits Per Employee | $-236,228.57 |
| Employee Count | 35 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 0.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -84.29% in the
last 52 weeks. The beta is 4.33, so RedHill Biopharma's
price volatility has been higher than the market average.
| Beta | 4.33 |
| 52-Week Price Change | -84.29% |
| 50-Day Moving Average | 2.4 |
| 200-Day Moving Average | 6.37 |
| Relative Strength Index (RSI) | 35.75 |
| Average Volume (20 Days) | 294,159 |
Income Statement
In the last 12 months, RedHill Biopharma had revenue of 8.04M
and earned -8.27M
in profits. Earnings per share was -512.
| Revenue | 8.04M |
| Gross Profit | 4.85M |
| Operating Income | -14.61M |
| Net Income | -8.27M |
| EBITDA | -7.59M |
| EBIT | -8.21M |
| Earnings Per Share (EPS) | -512 |
Full Income StatementBalance Sheet
The company has 4.62M in cash and 356K in
debt, giving a net cash position of 4.26M.
| Cash & Cash Equivalents | 4.62M |
| Total Debt | 356K |
| Net Cash | 4.26M |
| Retained Earnings | -414.8M |
| Total Assets | 18.04M |
| Working Capital | -10.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.37M
and capital expenditures -9K, giving a free cash flow of -9.38M.
| Operating Cash Flow | -9.37M |
| Capital Expenditures | -9K |
| Free Cash Flow | -9.38M |
| FCF Per Share | -1.45 |
Full Cash Flow StatementMargins
Gross margin is 60.31%, with operating and profit margins of -181.69% and -102.8%.
| Gross Margin | 60.31% |
| Operating Margin | -181.69% |
| Pretax Margin | -102.8% |
| Profit Margin | -102.8% |
| EBITDA Margin | -94.42% |
| EBIT Margin | -181.69% |
| FCF Margin | -116.6% |
